– Real-World Assessment of Impact of Initiating LYBALVI® (olanzapine and samidorphan) on Acute Care Events in Patients with Schizophrenia or Bipolar I Disorder and Comorbid Alcohol Use Disorder –
– Results from the
Alkermes plc (NASDAQ:ALKS) announced today that management will participate in two upcoming investor conferences.
Stifel 2026 Healthcare Conference
Date/Time: Fireside chat on Tuesday, Nov. 10, 2026 at 10:40 a.m. ET
Alkermes plc (NASDAQ:ALKS) today reported financial results for the quarter ended September 30, 2026. To view the detailed third quarter 2026 earnings press release and presentation, please visit the company’s investor
— Proof-of-Concept Study to Evaluate Effects of Orexin 2 Receptor Agonist on Symptoms of Depression in Adults With and Without Excessive Daytime Sleepiness —
Alkermes plc (NASDAQ:ALKS) today announced the initiation
Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to discuss the company’s third quarter financial results.
The webcast
— Data From Vibrance-1 Phase 2 Study Lancet Neurology Publication Evaluating Alixorexton in Narcolepsy Type 1 and Additional Data From Long-Term Extension Study in Narcolepsy Type 1 and Type 2 to be Shared in Oral
— ALKS 7290 is the First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful Improvements in ADHD Symptoms in Adults —
— ALKS 7290 Was Generally Well Tolerated at All Doses Tested in Healthy Volunteers and
Alkermes plc (NASDAQ:ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company’s Board of Directors (the Board). Ms. Whitaker is a seasoned biopharmaceutical executive and
— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project —
— Areas of Interest Expanded to Include Narcolepsy and Idiopathic Hypersomnia in Addition to Schizophrenia and Bipolar I Disorder
Tortugas Neuroscience ("Tortugas"), a clinical-stage central nervous system (CNS)-focused biotech company developing medicines with clinically validated mechanisms of action in indications with both substantial
– Alixorexton Demonstrated Statistically Significant and Clinically Meaningful Improvements in Wakefulness and Cataplexy –
– At All Doses Tested, Alixorexton Demonstrated Clinically Meaningful Improvements in
Alkermes plc (NASDAQ:ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press release and presentation, please visit the company’s investor
Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 28, 2026 to discuss the company’s second quarter financial results.
The webcast player
— First Long-Term Study of an Orexin 2 Receptor Agonist to Demonstrate Sustained Clinically Meaningful Improvements in Wakefulness and Excessive Daytime Sleepiness for Up to Nine Months in Narcolepsy Type 1 and Type 2
— First Large Phase 2 Study of an Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Improvements in Wakefulness and Excessive Daytime Sleepiness Compared to Placebo in
